Implant Sciences Wins 50 Unit German Airport Order; Market Recognition of Superior Technology Fuels European Market Expansion

WILMINGTON, Mass., July 30, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced an important sale of 50 of its QS-B220 desktop explosives trace detectors to several international airports in Germany. 

"Among the German airports in this sale was an airport that is consistently recognized as one of the best and busiest airports in Europe. We were thrilled to work with the customer to develop a customized software configuration for the QS-B220 that met their specific requirements, which we then integrated into our newest release of our European Civil Aviation Conference (ECAC)-approved system," stated Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing. "Our German customer needed ETD technology that enabled them to screen very high volumes of passengers with an extremely low false alarm rate. The system we optimized out-performed the other ETD systems when tested in side by side airport trials. I'm happy to announce that these systems are shipping today, and this software upgrade will be implemented into our entire installed base of QS-B220s globally in the fall."

"With this sale, we have announced well over 800 systems sold to international EU airports since the end of April," added Implant Sciences' CEO, Dr. Bill McGann. "Our strong chemistry and engineering team is consistently able to deliver on customer requirements. Once again, Implant Sciences has proven that offering the very best performance and a willingness to work with customers to help them improve security is what wins business."

About the QS-B220 Desktop Explosives and Drugs Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 60 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:
Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116

SOURCE Implant Sciences Corporation

Related Links

http://www.implantsciences.com